Aptinyx Reopens Enrollment in Phase 2 Study of NYX-2925 for Chronic Pain

Aptinyx Reopens Enrollment in Phase 2 Study of NYX-2925 for Chronic Pain
Enrollment has resumed for Aptinyx's Phase 2 clinical trial of NYX-2925, an oral small molecule designed to treat chronic pain in adults with fibromyalgia, the company announced. The study (NCT04147858) is recommencing after being temporarily suspended in March due to the escalation of COVID-19 in the U.S. Aptinyx has assured patients that the company will take necessary safety precautions to minimize risk to study participants.  “We are very pleased to be restarting this study. It will build on the positive results from our first Phase 2 evaluation of NYX-2925 in patients with fibromyalgia," Norbert Riedel, PhD, Aptinyx's president and CEO, said in a press release. "In support of this recommencement, we have incorporated appropriate precautionary measures designed to conduct this follow-up study safely in the current COVID-19 environment,” he said.  The double-blind Phase 2 study — in which neither researchers nor participants know which patients are receiving the medication and which a placebo — will determine the efficacy and safety of NYX-2925 as a treatment for fibromyalgia in comparison with a placebo. An estimated 300 patients between the ages of 18 and 75 will be enrolled. After a one- to four-week screening period, the participants will be randomly assigned to receive once-daily oral doses of 50 mg of NYX-2925, 100 mg of NYX-2925, or a placebo over 14 weeks (approximately 3.5 months). The study's primary efficacy goal is to measure average daily pain intensity over 12 weeks, based on changes in a 10-point rating scale. Other metrics to be evaluated are patient-reported outcomes, pain reduction, fatigue, cognition, and quality of life. Patients are being enrolled at 25 study sites in 15 states in the U.S. More information can be f
Subscribe or to access all post and page content.